Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis - Scorecard - MDSpire

Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis

  • By

  • Syed N. Rahman

  • Kandala Keervani

  • Xiwen Zhao

  • Curtis J. Perry

  • Ping Mu

  • Darryl Martin

  • Wei Shen Tan

  • David G. Hesse

  • Daniel P. Petrylak

  • Joshua Warrick

  • Deepika Kumar

  • Peter A. Humphrey

  • Fady Ghali

  • May 11, 2026

  • 0 min

Share

Clinical Scorecard: Evolving Patterns in the Diagnosis of Variant Bladder Cancer: Insights from a National Retrospective Cohort Study

At a Glance

CategoryDetail
Condition
Key MechanismsDistinct histological features, aggressive behavior, and different molecular drivers (e.g., mutations in TP53, RB1) compared to standard urothelial bladder cancer (UBC).
Target Population
Care Setting

Key Highlights

  • additional_context

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider distinct therapeutic approaches for VBC due to differing sensitivities to chemotherapy and immunotherapy, such as using targeted therapies based on molecular profiling.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with variant bladder cancer diagnosed from 2004 to 2021.

        VBC may require tailored treatment strategies due to its aggressive nature and different molecular characteristics.

        Clinical Best Practices

        • additional_recommendation

        Related Resources & Content

        Original Source(s)

        Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis

        • by Syed N. Rahman, Kandala Keervani, Xiwen Zhao, Curtis J. Perry, Ping Mu, Darryl Martin, Wei Shen Tan, David G. Hesse, Daniel P. Petrylak, Joshua Warrick, Deepika Kumar, Peter A. Humphrey, Fady Ghali

        • May 11, 2026

        Related Content

        From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

        Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

        Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort